Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis
14 Giugno 2023 - 10:01PM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today
announced it will host a webcast and conference call on Thursday,
June 15, 2023, at 8:00 a.m. (ET) to provide top-line results from
the Phase 3 INVIGORATE‑2 Trial of reproxalap in allergic
conjunctivitis.
The dial-in numbers are (833) 470-1428 for domestic callers and
(404) 975-4839 for international callers. The access code is
349573. A live audio webcast of the conference call also will be
accessible from the “Investors & Media” section of Aldeyra's
website at ir.aldeyra.com.
After the live webcast, the event will remain archived on
Aldeyra’s website for 90 days.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to
discovering innovative therapies designed to treat immune-mediated
diseases. Our approach is to develop pharmaceuticals that modulate
immunological systems, instead of directly inhibiting or activating
single protein targets, with the goal of optimizing multiple
pathways at once while minimizing toxicity. Our product candidates
include RASP (reactive aldehyde species) modulators ADX‑629,
ADX‑246, ADX‑248, and chemically related molecules for the
potential treatment of systemic and retinal immune-mediated
diseases. Our pre-commercial product candidates are reproxalap, a
RASP modulator for the potential treatment of dry eye disease
(under U.S. Food and Drug Administration New Drug Application
Review) and allergic conjunctivitis, and ADX-2191, a novel
formulation of intravitreal methotrexate for the potential
treatment of primary vitreoretinal lymphoma (under U.S. Food and
Drug Administration New Drug Application Priority Review),
proliferative vitreoretinopathy, and other rare sight-threatening
retinal diseases. For more information, visit
https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230614047620/en/
Investor & Media Contact: David Burke Tel: (917)
618-2651 investorrelations@aldeyra.com
Grafico Azioni Aldeyra Therapeutics (NASDAQ:ALDX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Aldeyra Therapeutics (NASDAQ:ALDX)
Storico
Da Mag 2023 a Mag 2024
